Skip to Main Content

Britain’s popular vote to leave the European Union seems likely to cause major disruptions for the drug approval process in the UK and across the channel in mainland Europe, analysts said Friday. There were also predictions that medical research funding will take a hit.

“The future structure of medicine regulation in Europe is now thrown into question,” said Steve Bates, CEO of the BioIndustry Association, a British life sciences trade organization.


The clearest impact of the “Brexit” vote on the life sciences sector is likely to fall on employees of the European Medicines Agency, which will likely have to relocate to another country, uprooting more than 600 people now working in London.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.